论文部分内容阅读
神经内分泌肿瘤(NEN)是起源于神经内分泌细胞或肽能神经元的一类肿瘤,可原发于全身多种脏器.NEN病理异质性大,患者预后差异大.常规影像学检查及病理学活组织检查对该病有重要意义,但均存在一定的局限性.NEN细胞常高度表达生长抑素受体(SSTR),且部分NEN因有高度增殖活性而表现出较高的葡萄糖代谢活性,这为核医学SSTR显像及葡萄糖代谢显像提供了分子基础.68 Ga-生长抑素类似物(SSA)/18F-脱氧葡萄糖(FDG)PET/CT联合显像可从受体表达及糖代谢活性方面综合评估NEN生物学特性,为NEN的病灶筛查、分级分期、治疗选择、疗效监测及预后判断等提供有效信息.该文总结了上述联合显像应用于NEN诊治的研究现况.“,”Neuroendocrine neoplasms (NEN) are tumors that originate from neuroendocrine cells or peptidergic neurons.NEN can be found in a variety of organs with high heterogeneity in pathology and large difference in prognosis.Conventional imaging methods and pathological biopsy have important roles in the diagnosis of NEN,while both of them have limitations.Most NEN cells highly express several peptide receptors,especially somatostatin receptors (SSTR).Moreover,some of them have high glycolysis activity because of high proliferative activity.68Ga-somatostatin analogs (68Ga-SSA) combined with 18F-fluorodeoxyglucose (18F-FDG) PET/CT imaging can comprehensively evaluate both the expression of SSTR and the activity of glycolysis in NEN,providing effective information for diagnosis,treatment,monitoring and prognosis.This review summarizes the current studies of combined 68Ga-SSA/18F-FDG PET/CT imaging in patients with NEN.